Edotreotide peptideyog ib qho kev xaiv ligand peptide uas tsom rau somatostatin receptor 2 (SSTR2). Nws ua tiav qhov kev kuaj mob thiab kho cov qog los ntawm kev khi rau SSTR2 nrog kev sib raug zoo siab. Cov peptide no muaj 8 amino acids thiab muaj cov disulfide daim ntawv cog lus nyob rau hauv nws cov qauv, uas muaj peev xwm tsim radiopharmaceuticals los ntawm chelating nrog radioactive isotopes (xws li ⁶⁸Ga, ¹⁷⁷Lu, ⁹⁰Y). Hauv kev kuaj mob, ⁶⁸Ga-labeled Edotreotide yog siv rau PET imaging los nrhiav SSTR-cov qog nqaij hlav neuroendocrine zoo (xws li lub plab hnyuv thiab pancreatic NETs, ntsws thiab thymus NETs), thiab nws cov qog noj ntshav nce mus txog li 8% ntawm cov tshuaj uas zoo sib xws, 30 feeb. Hauv thaj chaw kho mob, ¹⁷⁷Lu- sau npe Edotreotide induces qog cell apoptosis los ntawm kev tso tawm -rays, thiab kev sim tshuaj tau pom tias nws muaj lub hom phiaj tua neeg muaj zog rau cov qog nqaij hlav neuroendocrine xws li cov qog nqaij hlav qog nqaij hlav, ua rau cov neeg mob tsis muaj kev puas tsuaj ntau dua {14}, kom ntev li ntev tau cov ntaub so ntswg noj qab nyob zoo. Nws yog ib qho tshuaj sawv cev hauv peptide receptor radioisotope therapy (PRRT).
Peb cov khoom tsim
Edotreotide COA
Edotreotide peptideplays lub luag haujlwm tseem ceeb hauv kev kuaj mob neuroendocrine hlav (NETs). Nws tsim cov phiaj xwm duab los ntawm kev khi rau radioactive nuclides, ua rau siab - rhiab heev, meej hauv zos thiab kev ntsuam xyuas ntawm SSTR- cov qog zoo. Cov nram qab no piav qhia txog nws daim ntawv thov kuaj mob los ntawm ntau yam:
Core Diagnostic Technology: Somatostatin Receptor Imaging (SRI)
Lub ⁶⁸Ga-edotreotide tsim los ntawm kev sib xyaw ntawm edotreotide thiab gallium-68 (⁶⁸Ga) yog cov tseem ceeb reagent rau PET / CT duab. Nws tus nqi diagnostic nyob rau hauv:
Siab rhiab heev thiab tshwj xeeb
⁶⁸Ga-edotreotide muaj 3-fold ntau dua affinity rau SSTR2 piv rau cov tshuaj ib txwm siv (xws li ⁶⁸Ga-DOTATOC), uas ua rau muaj qhov nce loj hauv cov qog noj ntshav. Nws yog qhov tshwj xeeb tshaj yog rau kev kuaj pom cov kab mob me me (xws li metastases nrog txoj kab uas hla tsawg dua 5 hli). Cov ntaub ntawv kho mob qhia tau tias nws qhov kev kuaj pom tus kab mob plab hnyuv pancreatic NETs (GEP-NETs) ntau dua 90%, ua rau muaj txiaj ntsig zoo dua li cov qauv duab zoo li CT / MRI.
Cov duab nrawm thiab kev ntsuas dynamic
Cov qog ua haujlwm tuaj yeem ncav cuag 80% hauv 30 feeb tom qab txhaj tshuaj, ncav cuag qhov siab tshaj ntawm 70 ± 20 feeb. Lub sijhawm ntsuas lub sijhawm luv luv, tso cai kom ua tiav tag nrho - lub cev scans. Los ntawm cov duab dynamic, cov yam ntxwv hemodynamic ntawm cov qog tuaj yeem raug soj ntsuam, pab rau kev sib txawv ntawm cov kab mob benign thiab malignant.
Tag nrho -kev ntsuas lub cev thiab kev ua haujlwm
Ib qho kev txhaj tshuaj ib zaug tuaj yeem ua tiav tag nrho - lub cev qog nqaij hlav hauv zos, qhia meej txog cov kab mob loj thiab cov kab mob metastatic (xws li daim siab, pob txha, thiab cov qog ntshav qog ntshav), muab lub hauv paus tseem ceeb rau qog nqaij hlav (xws li AJCC staging system). Cov kev tshawb fawb tau pom tias ⁶⁸Ga-edotreotide imaging hloov qhov pib ntawm kwv yees li 30% ntawm cov neeg mob, cuam tshuam rau kev txiav txim siab kho mob.
Ua ntej- kev tshuaj xyuas kev kho mob thiab kev kwv yees kwv yees
Los ntawm kev ntsuas qhov qhia theem ntawm SSTR (xws li tus nqi SUVmax), qhov ua tau zoo ntawm peptide receptor radionuclide therapy (PRRT) tuaj yeem kwv yees. Cov neeg mob uas muaj SSTR siab qhia tau lub hom phiaj siab dua (ORR) rau ¹⁷⁷Lu- kho edotreotide dua li cov uas tsis tshua muaj kev qhia (21.9% vs. 4.2%).
Clinical application scenarios thiab qhov zoo
Kev kuaj mob ntxov thiab kuaj mob qog nqaij hlav asymptomatic
Neuroendocrine qog feem ntau tsis muaj cov tsos mob tshwj xeeb thaum ntxov. ⁶⁸Ga- kev kuaj pom edotreotide tuaj yeem kuaj pom cov qog me me hauv cov neeg mob asymptomatic, ua rau muaj kev cuam tshuam ntxov. Piv txwv li, pancreatic NETs tuaj yeem kuaj pom los ntawm kev ntsuas thaum txoj kab uas hla tsawg dua 2cm, thiab 5-xyoo txoj sia nyob tau nce ntxiv.
Kev kuaj mob sib txawv ntawm cov teeb meem nyuaj
Rau cov kab mob uas nyuaj rau kev txheeb xyuas kom meej los ntawm cov qauv duab (xws li CT/MRI), ⁶⁸Ga-edotreotide imaging tuaj yeem pab sib txawv raws li SSTR cov yam ntxwv. Piv txwv li, qhov zoo SSTR qhia nyob rau hauv lub ntsws nodules qhia tau hais tias muaj peev xwm ntawm cov qog nqaij hlav neuroendocrine, thaum cov txiaj ntsig tsis zoo yuav qhia tau tias mob ntsws cancer.
Kev saib xyuas kev kho mob thiab ua raws- nce
Thaum lub sij hawm PRRT los yog lub hom phiaj kev kho mob, ⁶⁸Ga-edotreotide imaging tuaj yeem soj ntsuam kev hloov pauv hauv cov qog nqaij hlav metabolic, ua kom pom ntxov ntawm kev kho mob lossis rov tshwm sim dua. Cov kev tshawb fawb tau pom tias lub sijhawm rau kev hloov pauv ntawm qhov tsis zoo mus rau qhov zoo yog 3-6 lub hlis ua ntej tshaj li ntawm CT / MRI, muab lub hauv paus rau kev kho cov phiaj xwm kho mob.
Kev kuaj mob qog nqaij hlav tshwj xeeb
Meningioma: Qee qhov meningiomas nthuav qhia SSTR, ⁶⁸Ga-edotreotide imaging tuaj yeem pab hauv kev npaj phais mob, txo qis cov seem tom qab phais.
Pediatric NETs: Los ntawm kev kho cov tshuaj tiv thaiv kab mob, nws tuaj yeem siv tau zoo rau cov neeg mob menyuam yaus, zam kev puas tsuaj ntau dhau.
Ntau tus kab mob endocrine adenoma (MEN): Nws tuaj yeem soj ntsuam cov qog nqaij hlav ntawm ntau lub cev endocrine (xws li pancreas, cov qog nqaij hlav parathyroid), ua kom yooj yim rau kev tswj cov txheej txheem.
Kev sib piv nrog cov txheej txheem kuaj mob ib txwm muaj
Piv nrog CT / MRI
rhiab heev:⁶⁸Ga- kev kuaj pom edotreotide muaj qhov kuaj pom ntau dua rau cov kab mob me dua li CT/MRI, tshwj xeeb tshaj yog rau kev kuaj pom cov metastases hauv cov kabmob xws li daim siab thiab pob txha.
Qhov tshwj xeeb:Los ntawm cov yam ntxwv ntawm SSTR, nws tuaj yeem txo cov txiaj ntsig tsis zoo los ntawm qhov tsis yog - qog nqaij hlav (xws li daim siab hemangiomas, pob txha Islands tuaj).
Cov ntaub ntawv ua haujlwm:Nws muab cov ntaub ntawv hais txog qog nqaij hlav metabolic, pab kev sib txawv ntawm cov kab mob benign thiab malignant thiab ntsuam xyuas cov kab mob.
Piv nrog biomarker nrhiav pom
Chromogranin A (CgA):Txawm hais tias nws yog ib hom tshuaj biomarker rau NETs, nws qhov kev nkag siab tsuas yog li 70%, thiab nws cuam tshuam los ntawm cov tshuaj (xws li proton twj tso kua mis inhibitors). ⁶⁸Ga- edotreotide imaging tuaj yeem ua rau nws qhov tsis txaus thiab ua tiav ob qho kev ntsuas ntawm morphology thiab kev ua haujlwm.
Kev kuaj tshuaj hormones:Rau kev ua haujlwm NETs (xws li insulinoma thiab gastrinoma), kev kuaj tshuaj hormone tuaj yeem pab hauv cheeb tsam, tab sis tsis yog- cov qog ua haujlwm yuav tsum tau cia siab rau cov txheej txheem kev tshuaj xyuas.
Tshawb nrhiav Frontiers thiab Technology Optimization
Kev tshawb nrhiav tshiab qhia
Cov ntawv thov tsis yog-NETs: Kev tshawb fawb tau pom tias qee qhov tsis yog-NETs xws li mob qog noj ntshav thiab lub raum cell carcinoma kuj qhia SSTR. ⁶⁸Ga-edotreotide imaging tej zaum yuav nthuav nws daim ntawv thov.
-ray nuclide imaging: Piv txwv li, ²¹¹At-labeled Edotreotide, nws -ray cov ntaub so ntswg nkag qhov tob yog luv dua, uas yuav txhim kho qhov kev tshawb pom rhiab heev ntawm qhov txhab me me.
Kev txhim kho tshuab
Dual receptor targeted imaging: Tsim ib tug complex uas ib txhij lub hom phiaj SSTR2 thiab GLP-1R kom nce qog uptake tus nqi thiab kev kuaj mob tshwj xeeb.
Nanotechnology: Muab Edotreotide nrog nanoparticles los txhim kho cov tshuaj ruaj khov thiab cov qog nkag tau, thiab txhim kho cov duab zoo.
Artificial txawj ntse{0}} pab kuaj mob
Los ntawm kev txheeb xyuas cov duab Ga-edotreotide cov duab uas siv cov txheej txheem kev kawm sib sib zog nqus, lub nra hnyav tuaj yeem raug txiav txim siab, cov lus teb kho mob tuaj yeem kwv yees, thiab kev kuaj mob tau zoo thiab raug tuaj yeem txhim kho.
Edotreotide peptideyog ib qho ligand peptide tsom rau somatostatin receptor 2 (SSTR2). Nws qhia tau tias muaj kev ruaj ntseg thiab kev nyab xeeb yam ntxwv hauv kev kho mob neuroendocrine hlav (NETs). Nws cov txiaj ntsig tseem ceeb yog nyob rau hauv kev ruaj ntseg ntawm cov qauv tshuaj, kev ua tau zoo ntawm kev xa khoom, thiab kev tswj xyuas cov kev mob tshwm sim.
Drug Structural Stability: Lub Foundation rau Ntev -Lub Sijhawm Ua Tau Zoo
Cov qauv tshuaj ntawm Edotreotide tau ua kom zoo thiab tsim kom muaj kev ruaj ntseg siab. Nws lub hauv paus ntsiab lus yog tsim los ntawm luv luv - saw amino acids, uas yog synthesized siv cov khoom siv -theem los yog kua-theem txheej txheem, tsim ib tug ruaj khov disulfide daim ntawv cog lus (yog tias yuav tsum tau muaj ntau yam disulfide bonds, tiv thaiv pawg xws li trt, Acm, thiab lwm yam. yog siv los xyuas kom meej qhov tseeb ntawm synthesis). Cov qauv kev ruaj ntseg no ua kom ntseeg tau tias Edotreotide tsis yooj yim hydrolyzed hauv lub cev, ua kom nws ib nrab -lub neej thiab tswj kom muaj txiaj ntsig zoo ntawm cov tshuaj ntshav. Piv txwv li, nyob rau hauv kev sim tshuaj ntawm plab hnyuv kab mob pancreatic neuroendocrine hlav (GEP-NETs), cov neeg mob tau txais 177Lu- kho edotreotide ib zaug txhua 3 lub hlis, ua tiav kev tswj cov qog tsis tu ncua thiab txo qhov xav tau kev tswj hwm ntau zaus.
Tsis tas li ntawd, cov txheej txheem chelation ntawm Edotreotide nrog cov xov tooj cua nuclides (xws li 177Lu, 90Y, 68Ga) yog cov paub tab, thiab cov tsim hluav taws xob sib txuas tseem nyob ruaj khov thaum khaws cia thiab thauj mus los. Cov kev tshawb fawb tau pom tias 177Lu-edotreotide tuaj yeem khaws cia rau 2 xyoos ntawm -80℃thiab 1 xyoo ntawm -20 degree. Tom qab thawing, cov tshuaj tswj kev ruaj ntseg rau 6 lub hlis, ua kom muaj kev ntseeg siab rau kev siv tshuaj kho mob.
Targeted Delivery Efficiency: Precise Killing and Low Off -Tej Hom Tshuaj Toxicity
Qhov siab ntawm Edotreotide rau SSTR2 (3 zaug siab dua li cov tshuaj ib txwm muaj xws li DOTATOC) yog tus yuam sij rau nws txoj kev nyab xeeb. Los ntawm kev sib tw khi rau SSTR2, Edotreotide tau xa cov xov tooj cua nuclide rau cov qog hlwb. Lub -rays (nrog rau cov ntaub so ntswg nkag qhov tob ntawm kwv yees li 2 hli) ncaj qha induce qog cell apoptosis thaum txo kev puas tsuaj rau cov ntaub so ntswg ib puag ncig. Piv txwv li:
GEP-NETs kev kho mob:Hauv kev sim COMPETE, qhov kev nce qib nruab nrab ntawm -kev muaj sia nyob dawb (mPFS) ntawm 177Lu-edotreotide pawg tau mus txog 23.9 lub hlis, ntev dua li ntawm pawg everolimus (14.1 lub hlis), thiab qhov tshwm sim ntawm kev kho mob- cuam tshuam txog kev mob tshwm sim qis dua (82.5%).
Kev kho mob ntsws thiab thymus NETs:Kev sim LEVEL tau pom tias 177Lu-edotreotide tuaj yeem ua rau ntev mPFS ntawm cov neeg mob ntsws cancer NET thiab thymic cancer (TC), thiab qhov tshwm sim ntawm cov kev mob tshwm sim loj xws li myelodysplastic syndrome (xws li, pob txha pob txha) tsuas yog 1 rooj plaub (qib 2), qis dua li ntawm cov tshuaj khomob.
Qhov "low{0}}toxicity thiab high-efficiency" tus yam ntxwv yog los ntawm lub hom phiaj ntawm Edotreotide: cov tshuaj absorbed hauv cov qog nqaij hlav siab, thaum cov ntaub so ntswg noj qab haus huv (xws li ob lub raum) txo cov hluav taws xob los ntawm lub raum tiv thaiv amino acid tov, thiab lub raum toxicity raug txo los ntawm 60% hauv kev sim.
Controllable Side Effect Management: Txhim khu kev kho mob siab
Kev nyab xeeb ntawm Edotreotide tau raug txheeb xyuas hauv ntau qhov kev sim tshuaj:
Thaum kho nrog 177Lu-edotreotide, qhov tshwm sim ntawm qib 3-4 cov xwm txheej lom (xws li neutropenia thiab thrombocytopenia) tsawg dua 10%, thiab feem ntau yog ncua sijhawm. Cov no tuaj yeem txo qis los ntawm kev hloov koob tshuaj lossis kev kho mob txhawb nqa.
Cov kev mob tshwm sim feem ntau suav nrog qaug zog (30% -50%), xeev siab (20% -30%), thiab mob raum tsis ua haujlwm (10% -15%). Feem ntau yog qib 1-2 thiab tsis xav tau kev kho mob cuam tshuam.
Ntev-lub sijhawm ua raws- nce pom tau tias 177Lu-edotreotide tsis ua rau muaj kev pheej hmoo ntawm kev mob qog nqaij hlav thib ob (xws li myelodysplastic syndrome, mob qog ntshav qab zib), thiab muaj kev cuam tshuam me me rau lub neej zoo (kev txhim kho tseem ceeb hauv tus neeg mob- qhia txog kev qaug zog thiab mob).
Cov neeg tshwj xeeb thiab kev nyab xeeb ntev -
Cov menyuam yaus:Los ntawm kev kho cov tshuaj radioactive (piv txwv li, 1.59 MBq / kg ib lub cev hnyav), Edotreotide qhia tau tias muaj kev nyab xeeb zoo hauv kev kho mob ntawm cov menyuam yaus NETs thiab tsis muaj kev mob tshwm sim ntev heev tau tshaj tawm.
Cov neeg mob lub raum tsis txaus:Cov txheej txheem tiv thaiv lub raum (xws li cov amino acid infusion) txo cov koob tshuaj hluav taws xob rau lub raum, ua rau cov neeg mob lub raum tsis txaus kom muaj kev nyab xeeb tau txais kev kho mob.
Ntev -kev kho mob lub sij hawm:Hauv kev sim COMPETE, 82.5% ntawm cov neeg mob tau ua tiav 4 lub voj voog ntawm kev kho mob, nrog kev ua raws ntau dua li cov pab pawg everolimus (nrog rau tus nqi siab ntawm 35% ntawm cov neeg mob txiav kev kho mob vim muaj kev phiv), qhia tias Edotreotide yog qhov tsim nyog rau kev siv sijhawm ntev -.
FAQ
1. Lub luag haujlwm tseem ceeb ntawm Edotreotide peptide yog dab tsi?
Edotreotide yog ib qho kev xaiv ligand peptide uas tsom rau somatostatin receptor 2 (SSTR2). Los ntawm kev khi rau radioactive nuclides (xws li ¹⁷⁷Lu, ⁶⁸Ga) los tsim cov kab mob radiolabeled, nws ua rau kev kuaj mob thiab kev kho mob ntawm SSTR- cov qog zoo. Nws cov haujlwm tseem ceeb suav nrog:
Kev kuaj mob: ⁶⁸Ga- edotreotide imaging tuaj yeem txheeb xyuas cov qog nqaij hlav neuroendocrine (NETs), nrog qhov rhiab heev tshaj 90%, zoo dua rau CT/MRI.
Kev Kho Mob: ¹⁷⁷Lu-edotreotide induces qog cell apoptosis los ntawm tso beta rays. Cov kev sim tshuaj ntsuam xyuas tau pom tias nws tuaj yeem ua kom ntev li kev loj hlob -dawb ciaj sia taus (PFS) ntawm cov neeg mob ntsws thiab thymus NETs, thiab cov kev mob tshwm sim tuaj yeem tswj tau.
2. Yuav ua li cas ruaj khov edotreotide peptide?
Kev ruaj ntseg ntawm edotreotide yog tshwm sim nyob rau hauv ob yam: tshuaj qauv thiab cia tej yam kev mob.
Cov qauv tshuaj: Nws cov molecule muaj disulfide bonds (Cys2-Cys7), uas yog synthesized siv cov khoom-theem los yog kua-theem txheej txheem los xyuas kom meej cov qauv stability. Thaum ua ke nrog cov xov tooj cua isotopes, cov txiaj ntsig ua haujlwm (xws li ¹⁷⁷Lu-edotreotide) tseem nyob ruaj khov thaum khaws cia thiab thauj mus los. Piv txwv li, nws tuaj yeem khaws cia rau 2 xyoos ntawm -80 degree, thiab cov tshuaj tseem nyob ruaj khov rau 6 lub hlis tom qab thawing.
Cia tej yam kev mob: hmoov daim ntawv yog pom zoo kom muab kaw kaw ntawm 2-8 degree. Daim ntawv tshuaj yuav tsum tsis txhob rov ua kom khov thiab thawing kom muaj kev ua si.
3. Edotreotide peptide muaj kev nyab xeeb npaum li cas?
Kev nyab xeeb ntawm Edotreotide tau raug txheeb xyuas hauv kev sim tshuaj. Nws qhov zoo muaj xws li:
Targeting: Precisely xa xov tooj cua nuclides los ntawm SSTR2 kom txo kev puas tsuaj rau cov ntaub so ntswg. Piv txwv li, hauv kev kho mob nrog ¹⁷⁷Lu-edotreotide, qhov tshwm sim ntawm qib 3-4 hematological toxicities (xws li neutropenia) tsawg dua 10%, thiab feem ntau yog ncua sijhawm.
Cov kev phiv uas tswj tau: Cov kev mob tshwm sim muaj xws li qaug zog thiab xeev siab (qib 1-2). Ntev - rov qab mus rau lub sij hawm tsis tau ua rau muaj kev pheej hmoo ntawm cov qog nqaij hlav thib ob.
Kev siv tau rau cov neeg tshwj xeeb: Los ntawm kev hloov koob tshuaj (xws li rau cov menyuam yaus ntawm 1.59 MBq / kg ib kg ntawm lub cev hnyav), Edotreotide tuaj yeem siv tau zoo rau cov menyuam yaus thiab cov neeg mob lub raum tsis txaus.
Cim npe nrov: Tuam Tshoj edotreotide peptide manufacturers, lwm tus neeg
